# A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

> **NCT07667803** · PHASE3 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 4500 (estimated)

## Conditions studied

- Weight Management

## Interventions

- **DRUG:** Elecoglipron
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07667803
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-29
- **Primary completion:** 2028-07-31
- **Final completion:** 2029-07-30
- **Target enrollment:** 4500 (ESTIMATED)
- **Last updated:** 2026-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07667803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07667803, "A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07667803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*